Overview

A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
Evaluation of the clinical and microbial efficacy of 0.6% ISV-403, compared to vehicle in the treatment of bacterial conjunctivitis.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch & Lomb Incorporated
Treatments:
Besifloxacin